The report is very thorough. It's worth paying for
Post# of 72435
![Avatar](/images/ProfileImages/398685088_3064_306524.png)
I think the peak sales for B-ABSSSI is too low ($300M). It should be $1B because that's what Daptomycin was making. The B-UP/UC market was too low as well. Not surprisingly, Amatuer17 was all over it. I also think the timeline for K-OC was too optimistic (partnership in 2017). Don't forget that the 1b part of the trial takes place first and it'll focus on safety.
I didn't pay much attention to the "sum-of-parts valuation" because it's more complicated than that. But it was fun reading it.
Quote:
what's your opinion of the report?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)